Kerrie Brady

Q: What is Kerrie Brady email address?

Email Kerrie Brady at kbrady@ocuterratx.com. This email is the most updated Kerrie Brady's email found in 2026.

Q: How to contact Kerrie Brady?

To contact Kerrie Brady send an email to kbrady@ocuterratx.com. (updated on April 17, 2024)

Board Member at Invea Therapeutics | Boston, Massachusetts, United States

About Kerrie Brady

Kerrie Brady is a seasoned biopharma executive and biotech entrepreneur with over 30 years of leadership experience in the pharmaceutical industry. Currently serving as a Board Member at Invea Therapeutics, she plays a pivotal role in guiding the strategic direction of this innovative clinical-stage biotechnology company. Invea is at the forefront of developing a groundbreaking pipeline of therapeutics powered by artificial intelligence and machine learning, specifically targeting immune-mediated inflammatory diseases (IMIDs). Kerrie's extensive expertise in biotechnology and her deep understanding of clinical development enable her to contribute significantly to the company's mission of transforming treatment paradigms for patients suffering from these complex conditions.

Throughout her career, Kerrie has successfully established funding and strategic collaborations that leverage emerging technologies, positioning companies to thrive in competitive markets. Her passion for science, coupled with her talent for business, has led to the successful commercialization of numerous biotech innovations. At Invea Therapeutics, she is actively involved in overseeing key projects that integrate advanced AI methodologies into drug development processes, enhancing the efficiency and effectiveness of therapeutic discovery.

Kerrie's skills in technology transfer, licensing, and venture capital are instrumental in navigating the complexities of the biotech landscape, ensuring that Invea remains at the cutting edge of therapeutic advancements. Her leadership in mergers and acquisitions further strengthens the company’s strategic partnerships, fostering an ecosystem of innovation that is essential for addressing the unmet needs in the treatment of IMIDs. With a proven track record of executive leadership, Kerrie Brady continues to be a driving force in the evolution of biopharma, making a lasting impact on the industry and the lives of patients.

Kerrie Brady Work